The Expression of miR-320b in Extracellular Vesicles as a Predictor of the Progression of Non-small Cell Lung Carcinoma and Its Association with Molecular and Clinical Therapy Response
Categoría del artículo: Research Article
Publicado en línea: 31 ene 2025
Páginas: 15 - 21
Recibido: 15 ene 2024
Aceptado: 04 jul 2024
DOI: https://doi.org/10.2478/fco-2023-0040
Palabras clave
© 2024 Wily Pandu Ariawan et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
Lung carcinoma remains a predominant contributor to cancer-related mortality globally. MicroRNAs (miRNAs) are pivotal regulators in carcinogenesis. Specifically, miR-320b is a tumor suppressor in the oncogenic process. This investigation probes the expression dynamics of miR-320b within extracellular vesicles (EVs) posttherapy in non-small cell lung cancer (NSCLC), correlating these patterns with differential therapeutic outcomes.
Patients and Methods
This analytical study employs a prospective cohort methodology including 16 advanced-stage NSCLC patients at Dharmais Cancer Hospital from November 2021 to August 2022. We obtained 12 ml of peripheral blood sequentially, pre- and post-therapy, encompassing chemotherapy, targeted, or radiotherapy. EVs were isolated utilizing the IZON qEV2 column, quantified via spectrophotometry, and further characterized using confocal microscopy. Statistical analyses were conducted with Statistical Package for the Social Sciences version 24.0.
Results
Participants (
Conclusions
Alterations in miR-320b expression within EVs posttherapy – decreases in the partial and stable disease cohorts and an increase in the progressive disease group – suggest a potential compensatory mechanism within the tumor milieu in reaction to therapeutic interventions. These statistically nonsignificant fluctuations underscore the complexity of miR-320b’s role and its prospective utility in gauging NSCLC progression.